Significant increases were observed in ICPs including CXCR5− nB, CXCR5− SMB, CXCR5− DNB, and PB in patients with new-onset SLE compared to HDs (median: CXCR5− nB SLE 3.049%, HD 0.435%, P < 0.0001; CXCR5− SMB SLE 0.716%, HD 0.267%, P = 0.0011; CXCR5− DNB SLE 1.450%, HD 0.236%, P < 0.0001; PB SLE 0.189%, HD 0.0236%, P < 0.0001). This evidence concerns the gene CXCR5 and systemic lupus erythematosus.